👤 Jennifer Spillane

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
2
Articles
2
Name variants
Also published as: Maria Spillane
articles
Anneke T Vulto-van Silfhout, Ingrid M Jazet, Suzanne Yzer +41 more · 2025 · Genetics in medicine : official journal of the American College of Medical Genetics · Elsevier · added 2026-04-24
A homozygous loss-of-function (LoF) variant in POC5 was previously described in an individual with retinitis pigmentosa. We identified POC5 variants in 12 probands with a syndromic phenotype. We aim t Show more
A homozygous loss-of-function (LoF) variant in POC5 was previously described in an individual with retinitis pigmentosa. We identified POC5 variants in 12 probands with a syndromic phenotype. We aim to define the phenotype spectrum and molecular mechanism associated with biallelic POC5 LoF variants. We studied a cohort of 12 families with bi-allelic LoF POC5 variants and performed detailed phenotype analysis. POC5 localization studies were performed in 3 proband-derived fibroblast cell lines. Detailed phenotyping of probands with POC5 variants expands the phenotype spectrum beyond ocular manifestations. This syndrome causes not only rod-cone dystrophy but also diabetes mellitus with severe insulin resistance and partial lipodystrophy, kidney disease, and muscle cramps. The POC5 protein plays an essential role during cell cycle and cilium formation. Interestingly, POC5 localization studies in 3 proband-derived fibroblast cell lines show aberrant localization suggesting a ciliary defect. The phenotypes of the 12 families in this study fit well within the ciliopathy phenotype spectrum, except for lipodystrophy, which is not common in ciliopathies. We describe a multiorgan syndrome caused by bi-allelic LoF variants in POC5. This underscores the pleiotropic effects of POC5 variants and highlights the significance of adipose tissue and metabolic dysfunction in ciliopathies. Show less
no PDF DOI: 10.1016/j.gim.2025.101513
POC5
Yu Jiang, Travis J Meyers, Adaeze A Emeka +94 more · 2022 · HGG advances · Elsevier · added 2026-04-24
Yu Jiang, Travis J Meyers, Adaeze A Emeka, Lauren Folgosa Cooley, Phillip R Cooper, Nicola Lancki, Irene Helenowski, Linda Kachuri, Daniel W Lin, Janet L Stanford, Lisa F Newcomb, Suzanne Kolb, Antonio Finelli, Neil E Fleshner, Maria Komisarenko, James A Eastham, Behfar Ehdaie, Nicole Benfante, Christopher J Logothetis, Justin R Gregg, Cherie A Perez, Sergio Garza, Jeri Kim, Leonard S Marks, Merdie Delfin, Danielle Barsa, Danny Vesprini, Laurence H Klotz, Andrew Loblaw, Alexandre Mamedov, S Larry Goldenberg, Celestia S Higano, Maria Spillane, Eugenia Wu, H Ballentine Carter, Christian P Pavlovich, Mufaddal Mamawala, Tricia Landis, Peter R Carroll, June M Chan, Matthew R Cooperberg, Janet E Cowan, Todd M Morgan, Javed Siddiqui, Rabia Martin, Eric A Klein, Karen Brittain, Paige Gotwald, Daniel A Barocas, Jeremiah R Dallmer, Jennifer B Gordetsky, Pam Steele, Shilajit D Kundu, Jazmine Stockdale, Monique J Roobol, Lionne D F Venderbos, Martin G Sanda, Rebecca Arnold, Dattatraya Patil, Christopher P Evans, Marc A Dall'Era, Anjali Vij, Anthony J Costello, Ken Chow, Niall M Corcoran, Soroush Rais-Bahrami, Courtney Phares, Douglas S Scherr, Thomas Flynn, R Jeffrey Karnes, Michael Koch, Courtney Rose Dhondt, Joel B Nelson, Dawn McBride, Michael S Cookson, Kelly L Stratton, Stephen Farriester, Erin Hemken, Walter M Stadler, Tuula Pera, Deimante Banionyte, Fernando J Bianco, Isabel H Lopez, Stacy Loeb, Samir S Taneja, Nataliya Byrne, Christopher L Amling, Ann Martinez, Luc Boileau, Franklin D Gaylis, Jacqueline Petkewicz, Nicholas Kirwen, Brian T Helfand, Jianfeng Xu, Denise M Scholtens, William J Catalona, John S Witte Show less
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prosta Show more
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion ( Show less
📄 PDF DOI: 10.1016/j.xhgg.2021.100070
MAST3